We present methods for the identification of protein-coding genes based on their patterns of nucleotide conservation across related species. We observed the pressure to conserve the reading frame of functional proteins and developed a test for gene identification with high sensitivity and specificity. We used this test to revisit the genome of S. cerevisiae, reducing the overall gene count by 500 genes (10% of previously annotated genes) and refining the gene structure of hundreds of genes. We present novel methods for the systematic de novo identification of regulatory motifs. The methods do not rely on previous knowledge of gene function and in that way differ from the current literature on computational motif discovery. Based on the genome-wide conservation patterns of known motifs, we developed three conservation criteria that we used to discover novel motifs. We used an enumeration approach to select strongly conserved motif cores, which we extended and collapsed into a small number of candidate regulatory motifs. These include most previously known regulatory motifs as well as several noteworthy novel motifs. The majority of discovered motifs are enriched in functionally related genes, allowing us to infer a candidate function for novel motifs.

Our results demonstrate the power of comparative genomics to further our understanding of any species. Our methods are validated by the extensive experimental knowledge in yeast, and will be invaluable in the study of complex genomes like that of human.

Address of the bookmark: http://web.mit.edu/manoli/www/publications/Kellis_JCB_04.pdf

ICRISAT is headquartered in Patancheru near Hyderabad, India, with two regional hubs and five country offices in sub-Saharan Africa. ICRISAT, established in 1972, is a member of the CGIAR Consortium. For more details, see www.icrisat.org.

Job Responsibilities:
Planning and execution of different NGS/genomics data analysis
Apply, maintain, and support cutting-edge pipelines for the analysis and interpretation of NGS data
Analyze large-scale genomic datasets generated internally and through collaboration with others
Genome wide analysis- LD analysis, hapmap, genetic map construction and qtl mapping
Expression analysis based on RNA-seq, gene ontology and metabolic pathway data
Sequence level analysis like gene family analysis, orthology/paralogy etc.
Familiarity with genomic and biological information databases
Compilation and interpretation of results and writing reports
Experience working independently and in a team environment
Requirements:

PhD or M.Sc with 2-3 years experience from reputed institute in the area of life science or similar Knowledge in Next Generation Sequencing (NGS) data analysis. Should be familiar with various sequencing platforms. Sound knowledge of genomics and molecular biology is must. Proficient in any one of the programming/scripting in languages: Python, Perl, PHP, R, Shell Scripting. Must be experienced in working on Linux and CLI environment. Ability to work as team as well as independently with minimal support. Fluency in spoken and written English is essential.

NGS techniques like sequence alignment, variant calling based on whole genome re-sequencing and genotyping-by-sequencing (GBS), RNA-Seq/transcriptome analysis
Knowledge of various standard NGS related tool
Ability to solve complex problems in advanced genomics research areas
Ease and interest in working with people from diverse backgrounds
Excellent oral/written communication and interpersonal/networking skills
General:
This position is contract for a period of two years.

How to apply:
Applicants should apply on or before 27-July-2017, with latest Curriculum Vitae, and the names and contact information of three references that are knowledgeable about your professional qualifications and work experience. All applications will be acknowledged, however only short listed candidates will be contacted
Please CLICK HERE to submit your application.
ICRISAT is an equal opportunity employer

http://icrisat.careersitemanager.com/job-listings-Visiting-Scientist-Computational-Genomics-ICRISAT-Hyderabad-Secunderabad-2-to-4-years-060717000278

AI and science working together to manage the root causes of your aging 

Personalized plan built from your biomarkers and devices

Biologically-active treatments (cellular health). No drugs.

Source is Linkedln link :

https://www.linkedin.com/company/5143768/

Address of the bookmark: https://suisselifescience.com/

Our capacity building activities covers both general and specialized topics in translational genetics, and is designed to better acquaint scientists and clinicians with the tools and technologies of genetics and genomics.

OUR RESEARCH ACTIVITIES INCLUDE:

Address of the bookmark: http://www.nabda.gov.ng/departments/genetics-genomics-and-bioinformatics

We also develop web-based applications that integrate data across domains to facilitate the forest geneticist or ecologist’s ability to analyze, share, and visualize their data. Such integration requires the implementation of semantic technologies and ontologies to connect genotype, phenotype, and environmental data.

http://plantcompgenomics.com/

Scientist C - Non-Medical (IT Expert- Computer Professional/Genomics/Bioinformatic)No. of posts: 01 (UR)

Salary (Fixed): Rs.51,000/- + HRA

Essential Qualification: Candidate should possess 1st class master degree in relevant subjects from a recognized university with 4 years experience
OR
2nd class M.Sc + Ph.D degree in relevant subjects from a recognized university with 4 years experience.Desirable Qualification: Candidates should possess a PhD degree in any field of science.
Preference will be given to those who have published scientific papers in international journals and who have a track record of working in infectious diseases.

The candidate must know the following for further consideration: (a) data processing and analysis using statistical softwares, (d) programming, (e) presentation of complex data from excel files and related skills.
Understanding of GIS and malaria will be an advantage. Experience and interest in functional genomics and genomic sequencing will be important.

Age Limit: 40 YearsDuration: 30.09.2021

More at http://onlineapply.nimr.org.in/

GIC2024 focuses on "Advances In Genomics From AI-ML To Targeted
Therapies". GIC2024 encourages researchers to present original
contributions for poster presentations.

Note: Early bird registration closes on 1st December 2023.

Kindly, register at GIC 2024 Earlybird registartion

https://genomicsindia.co.in/

More at https://rennisonlab.com/

The Power of Evo 2: AI Meets DNA

Evo 2 is the largest AI model for biology ever created, trained on an astonishing 9.3 trillion DNA "letters" (nucleotides) carefully selected from genomes spanning the entire tree of life. This massive dataset ensures that Evo 2 can recognize patterns and relationships in genetic sequences at an unparalleled scale.

For the first time, scientists can design DNA with AI, moving beyond simple sequence analysis to active DNA generation. Evo 2 enables researchers to predict, modify, and even create entire genetic sequences, opening new possibilities in medicine, agriculture, and synthetic biology.

Decoding the Dark Genome

One of the biggest challenges in genetics is understanding the non-coding regions of DNA—vast stretches of the genome that do not code for proteins but play crucial roles in regulating gene expression. These regions control when and how genes are activated, influencing everything from development to disease.

Evo 2 is designed to decode these non-coding elements, helping researchers uncover their functions and use this knowledge to develop gene-based therapies, synthetic life forms, and precision agriculture solutions.

From Reading DNA to Writing It

To put Evo 2’s impact into perspective:

• Previous AI models could "read" DNA like a book, analyzing genetic sequences and identifying patterns.
• Evo 2 can "write" entirely new DNA, designing functional genes, chromosomes, and even full genomes from scratch.

This means scientists can now engineer biological systems with AI, designing new proteins, metabolic pathways, and genetic circuits to address real-world challenges.

A Step Toward Generative Biology

The Arc Institute describes Evo 2 as a major step toward "generative biology"—a revolutionary approach where AI is used to create novel biological structures rather than just analyzing existing ones. This could lead to breakthroughs such as:

• New medicines: AI-generated enzymes and proteins tailored for targeted therapies.
• Disease-resistant crops: Genetically optimized plants for higher yield and climate resilience.
• Synthetic organisms: Custom-designed microbes for bioremediation, biofuel production, and industrial applications.

An Open-Source Revolution

Unlike many proprietary AI models, Evo 2 is open source, making its capabilities accessible to researchers worldwide. This democratization of AI-driven biology means that scientists from different disciplines can collaborate, experiment, and innovate, accelerating discoveries in genetic engineering and synthetic biology.

With Evo 2, the boundaries of what’s possible in DNA design, genetic engineering, and biological innovation are being redrawn. The future of life sciences is no longer just about understanding life’s code—it’s about writing it.

Source:http://www.nejm.org/doi/full/10.1056/NEJMp1114866

Another video on precision medicine:

http://www.youtube.com/watch?v=Pi8W0yOXnzE

Precision Medicine basically intergrates bioinformatics, genomics , genetics, molecular biology and nanotechnology to deliver precise cure/diagnotics to a specific patient.

Examples:

• The drug imatinib (Gleevec) designed to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenous leukemia.
• The breast cancer drug trastuzumab (Herceptin) works only for women whose tumors have a particular genetic profile called HER-2 positive.

E.g. source :

http://www.bionews-tx.com/news/2013/08/15/how-the-impact-of-cancer-genomics-on-precision-medicine-is-revolutionizing-cancer-treatment/

Address of the bookmark: http://www.cbsnews.com/video/watch/?id=50149783n